Knowledge Synthesis Group, Clinical Epidemiology Program, Ottawa Hospital Research Institute, Centre for Practice-Changing Research, 501 Smyth Road, Box 201, Ottawa, Ontario, K1H 8L6, Canada.
Public Health Agency of Canada, Ottawa, Ontario, Canada.
Syst Rev. 2019 Jan 19;8(1):28. doi: 10.1186/s13643-018-0928-x.
Tobacco smoking is the leading cause of cancer, preventable death, and disability. Smoking cessation can increase life expectancy by nearly a decade if achieved in the third or fourth decades of life. Various stop smoking interventions are available including pharmacotherapies, electronic cigarettes, behavioural support, and alternative therapies. This protocol outlines an evidence review which will evaluate the benefits and harms of stop smoking interventions in adults.
The evidence review will consist of two stages. First, an overview of systematic reviews evaluating the benefits and harms of various stop smoking interventions delivered in or referred from the primary care setting will be conducted. The second stage will involve updating a systematic review on electronic cigarettes identified in the overview; randomized controlled trials will be considered for outcomes relating to benefits while randomized controlled trials, non-randomized controlled trials, and comparative observational studies will be considered for evaluating harms. Search strategies will be developed and peer-reviewed by medical information specialists. The search strategy for the updated review on e-cigarettes will be developed using that of the candidate systematic review. The MEDLINE®, PsycINFO, Embase, and the Cochrane Library electronic databases will be searched as of 2008 for the overview of reviews and from the last search date of the selected review for the updated review. Organizational websites and trial registries will be searched for unpublished or ongoing reviews/studies. Two reviewers will independently screen the title and abstracts of citations using the liberal accelerated method. Full-text screening will be performed independently by two reviewers. Extracted data will be verified by a second reviewer. Disagreements regarding full-text screening and data extraction will be resolved by consensus or third-party adjudication. The methodological quality of systematic reviews, risk of bias of randomized and non-randomized trials, and methodological quality of cohort studies will be evaluated using AMSTAR 2, the Cochrane risk of bias tool, and a modified version of the Scottish Intercollegiate Guidelines Network critical appraisal tool, respectively. The GRADE framework will be used to assess the quality of the evidence for outcomes.
The evidence review will evaluate the benefits and harms of various stop smoking interventions for adults. Findings will be used to inform a national tobacco cessation guideline by the Canadian Task Force on Preventive Health Care.
PROSPERO (CRD42018099691, CRD42018099692).
吸烟是癌症、可预防死亡和残疾的主要原因。如果在生命的第三或第四十年戒烟,可以使预期寿命延长近十年。各种戒烟干预措施包括药物治疗、电子烟、行为支持和替代疗法。本方案概述了一项证据审查,该审查将评估在初级保健环境中提供或转介的各种戒烟干预措施的益处和危害。
证据审查将包括两个阶段。首先,将对评估在初级保健环境中提供或转介的各种戒烟干预措施的益处和危害的系统评价进行概述。第二阶段将涉及更新电子香烟的系统评价;将考虑随机对照试验来评估与益处相关的结果,而随机对照试验、非随机对照试验和比较观察性研究将用于评估危害。将由医学信息专家制定和审查搜索策略。更新的电子烟综述的搜索策略将使用候选系统评价的搜索策略。将从 2008 年开始,使用 MEDLINE、PsycINFO、Embase 和 Cochrane 图书馆电子数据库对综述进行概述,并从选定综述的最后一次检索日期起对更新的综述进行检索。将搜索组织网站和试验登记处,以查找未发表或正在进行的综述/研究。两位审查员将使用宽松的加速方法独立筛选标题和摘要。将由两名审查员独立进行全文筛选。提取的数据将由第二名审查员验证。如果在全文筛选和数据提取方面存在分歧,将通过协商或第三方裁决解决。将使用 AMSTAR 2、Cochrane 偏倚风险工具和苏格兰校际指南网络批判性评价工具的修改版分别评估系统评价的方法学质量、随机和非随机试验的偏倚风险以及队列研究的方法学质量。将使用 GRADE 框架评估结局的证据质量。
该证据审查将评估各种成人戒烟干预措施的益处和危害。研究结果将用于为加拿大预防保健特别工作组提供国家戒烟指南。
PROSPERO(CRD42018099691、CRD42018099692)。